News

Precision under pressure: logistics facts shaping nuclear medicine scalability

This plan centers on documented facts about nuclear medicine logistics and Technetium-99m. It keeps the article evidence-led by focusing on supply-chain strain, current trial activity, and basic reference points readers can verify.

Why innovation alone is no longer enough in biopharma

Innovation alone is no longer enough in biopharma because execution, speed, trust, and compliance now shape competitive outcomes. This plan focuses on the market signal, why it matters, and what pharma teams should watch next.

FDA Approves Lumasiran for AHP: What BD and Investors Should Know

This rewrite clarifies that FDA-approved Givlaari (givosiran) is indicated for adults with acute hepatic porphyria, while OXLUMO (lumasiran) is approved for PH1. The article should frame the catalyst as a regulatory and portfolio update, not a new AHP label for lumasiran.

Breast Cancer Statistics Worldwide: What the Data Shows

Breast cancer remains the most common cancer in women across many markets, with 2.3 million new cases estimated globally each year. This plan frames the latest data for pharma teams, including age distribution, lifetime risk, and U.S. trend signals.

Manufacturing pipeline approvals: what the evidence confirms

This plan covers what a manufacturing pipeline means, what EWIB does, and what the Eastern CT Manufacturing Pipeline Initiative publicly confirms. It stays tightly grounded in the available evidence and avoids unsupported outlook claims.

GLP-1 usage statistics show broad uptake and mixed clinical signals

GLP-1 usage statistics show that 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year, with 2.9% using it for weight loss. New research also highlights meaningful benefits alongside kidney, pancreas, and gastrointestinal risks, shaping the latest research on GLP-1 for pharma teams.

Novo Nordisk supply of Wegovy stabilizes as new capacity comes online

Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.

BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial

BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.

MariTide Phase 2 obesity data show up to 20% weight loss at one year

Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.

GSK’s Blenrep returns to the US market after FDA approves resubmission

The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.

Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response

Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.

Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win

Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.

Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing

Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.

FDA approves Vyloy for HER2-negative gastric and GEJ cancer

The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.

Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends

Novo Nordisk supply Wegovy stabilizes as the FDA says the shortage of Wegovy and Ozempic is resolved. The change follows new and planned manufacturing capacity, with implications for access, competition, and BD strategy.

J&J reports positive Phase 3 Tremfya data in ulcerative colitis

Johnson and Johnson reported positive Phase 3 data for Tremfya in ulcerative colitis, adding to its IBD catalyst set. The plan below frames the data, the approval backdrop, and the next milestones investors should watch.

Sanofi completes Inhibrx acquisition for $1.7B

Sanofi agreed to buy all outstanding Inhibrx shares for $30.00 in cash, valuing the company at about $1.7 billion. The merger closed on May 30, 2024, making Inhibrx an indirect wholly owned Sanofi subsidiary.

MariTide Phase 2: Amgen reports up to 20% weight loss at one year

Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.

FDA approves Dupixent for COPD with eosinophilic phenotype

The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.

GSK Blenrep wins FDA approval in relapsed multiple myeloma

GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.